IJCS | Volume 33, Nº1, January / February 2019

71 Cont. Table 1 - Demographic and clinical characteristics of 377 adult patients admitted with atrial fibrillation at a tertiary hospital in Salvador, Bahia, Brazil Variable Without anticoagulant (n = 93) With anticoagulant (n = 284) p* VKA (n = 76) DOACs (n = 208) p† AF classification n = 339 Paroxysmal 35 (41.7) 106 (41.6) 0.185 20 (27.8) 86 (47) 0.002 Persistent 5 (6) 35 (13.7) 13 (18.1) 22 (12) Permanent 28 (33.3) 64 (25.1) 28 (38.9) 36 (19.7) Undetermined 16 (19) 50 (19.6) 11 (15.3) 39 (21.3) CHA 2 DS 2 -VASc 4 (0 to 8) 3 (0 to 9) 0.010 3 (0 to 8) 3 (0 to 9) 0.199 HASBLED 2 (0 to 4) 1 (0 to 4) < 0.001 1 (0 to 4) 1 (0 to 4) 0.089 Recent ischemic stroke/TIA 4 (4.3) 21 (7.4) 0.298 6 (7.9) 15 (7.2) 0.846 Recent hemorrhagic stroke 2 (2.2) 0 (0) 0.013 0 0 Biological prosthesis 2 (2.2) 13 (4.6) 0.299 9 (11.8) 4 (1.9) < 0.001 Metallic prosthesis 0 (0) 7 (2.5) 0.126 7 (9.2) 0 (0) < 0.001 Valvular heart disease 23 (24.7) 70 (24.6) 0.987 28 (36.8) 42 (20.2) 0.004 Hemorrhage 9 (9.7) 12 (4.2) 0.047 5 (6.6) 7 (3.4) 0.233 Major bleeding 4 (4.3) 5 (1.8) 0.164 2 (2.6) 3 (1.4) 0.500 Interaction with DOAC 60 (64.5) 225 (79.2) 0.004 67 (88.2) 158 (76) 0.025 Creat. (mg/dl), n = 350 1.1 ± 0.9 1.1 ± 0.7 0.986 1.3 ± 1.3 1 ± 0.3 0.031 LA (mm), n = 349 42.6 ± 7.4 43.5 ± 6.6 0.283 47.3 ± 6.14 42.2 ± 6.3 < 0.001 LVEF (%), n = 349 62.1 ± 12.9 59.8 ± 15 0.176 55.1 ± 16 61.5 ± 14.5 0.002 Arrhythmia reversal Electric 10 (10.8) 82 (28.9) < 0.001 19 (25) 63 (30.3) 0.005 Not Executed 41 (44.1) 100 (35.2) 40 (52.6) 60 (28.8) Chemical 30 (32.3) 41 (14.4) 6 (7.9) 35 (16.8) Spontaneous 10 (10.8) 41 (14.4) 7 (9.2) 34 (16.3) Ablation 02 (2.2) 20 (7) 4 (5.3) 16 (7.7) Antiplatelet agents 56 (60.2) 3 (15) < 0.001 13 (17.1) 30 (14.4) 0.577 For continuous variables n (± standard deviation) and for continuous variables n (%); in case of missing data, total n was placed next to the variable; p* refers to comparison between groups with and without anticoagulants; p† refers to comparison between the groups with VKA and DOAC; TCA: transcutaneous coronary angioplasty; TIA: transient ischemic attack; Creat.: serum creatinine; LA: left atrium; LVEF: left ventricular ejection fraction. Geraldes et al. Oral anticoagulation in AF Int J Cardiovasc Sci. 2020;33(1):68-78 Original Article From 2011 to 2015, there was a progressive increase in the use of anticoagulants from 64% to 87%, largely at the expense of an increase in the use of DOACs, which rose from 29% to 70% (a relative increase of 144.8%), and reduced use of VKA and antiplatelets alone in the same period. Average annual incorporation of DOACs was 10.4% (Chart 2). About 25% of the patients were on antiplatelets alone or combined with anticoagulants. The prevalence of prescription of oral anticoagulants, antiplatelets and no antithrombotic drugs stratified by risk category according to the CHA 2 DS 2 -VASc and HASBLED scores are shown in charts 3 and 4. There